Precision Medicine in Alzheimer's Disease: Integration of Resilience Metrics and Risk Factors - Validation Cohort BioCogBank-AD
Status: Recruiting
Location: See location...
Intervention Type: Other, Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
BioCogBankAD aims at building a prospective clinical practice cohort of 244 patients with biologically confirmed mild cognitive impairment due to Alzheimer's Disease (AD) or mild AD in order to validate data regarding markers of resilience toward AD pathophysiological process discovered in an upstream project called AD-Resilience.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Maximum Age: 90
Healthy Volunteers: f
View:
• Diagnosis of AD according to IWG-2 2014 criteria
• Age 50-90 year old
• Affiliated or beneficiary of a social security scheme
• MMSE ≥ 20
• Abnormal CSF Aβ42 or Aβ40/Aβ42 ratio according to local cut-offs
• Abnormal CSF phosphorylated and total Tau according to local cut-offs
• Ability to pass neuropsychological assessments
• Availability of a brain MRI with T1 volumetric sequence performed within 1 year
Locations
Other Locations
France
Hôpital Cochin
RECRUITING
Paris
Contact Information
Primary
Olivier HANON, MD, PhD
olivier.hanon@aphp.fr
+ 1 44 08 33 81
Backup
Valérie PLENCE, MSc
valerie.plence@aphp.fr
+33 1 54 41 11 78
Time Frame
Start Date: 2024-10-31
Estimated Completion Date: 2027-09
Participants
Target number of participants: 244
Treatments
Experimental: Exploratory group
Related Therapeutic Areas
Sponsors
Collaborators: National Research Agency, France, Institut National de la Santé Et de la Recherche Médicale, France, Centre National de la Recherche Scientifique, France
Leads: Assistance Publique - Hôpitaux de Paris